Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Dr Vasquez on NAPRT as a Potential Biomarker for NAMPT Inhibition in Pediatric Rhabdomyosarcoma

May 22nd 2025

Juan Vasquez, MD, discusses how loss of NAPRT expression may serve as a biomarker for antitumor activity with NAMPT inhibition in rhabdomyosarcoma.

Experts Spotlight Noteworthy GU Cancer Abstracts Ahead of the 2025 ASCO Annual Meeting

May 22nd 2025

Ahead of the 2025 ASCO Annual Meeting, experts in genitourinary cancers share the most anticipated research being presented during the meeting.

Improved Public Awareness and Immunotherapy Drive Down Melanoma Mortality Amid Rising Incidences

May 21st 2025

Vincent Ma, MD, discusses progress in the management of advanced-stage melanoma and the need for primary prevention during Skin Cancer Awareness Month.

China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL

May 21st 2025

Tafasitamab plus lenalidomide has received NMPA approval for patients with relapsed/refractory DLBCL who are ineligible for ASCT.

Cortice Biosciences Transfers Orphan Drug Designations for TPI 287 in Brain Cancer and CNS Diseases

May 21st 2025

CNS Pharmaceuticals has acquired the orphan drug designations for TPI 287 in gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.

TNBC Treatment Innovations Build on ADC Optimization, Provide Impetus for Individualized Care

May 21st 2025

Alexis LeVee, MD, discusses ongoing phase 3 trials evaluating the first-line use of ADCs in both PD-L1–positive and –negative TNBC.

Dr Vonderheide on Responses With RAS(ON) Inhibition in Preclinical Pancreatic Cancer Models

May 20th 2025

Robert Herman Vonderheide, MD, DPhil, discussed potential immune responses with immunotherapy plus KRAS inhibition in pancreatic cancer models.

Dr Tykodi on the Current Limitations of Cabozantinib-Based Triplets in Advanced RCC

May 20th 2025

Scott Tykodi, MD, PhD, discusses the challenges with developing effective, less toxic triplet regimens for patients with advanced RCC.

Dr Orgueira on Refining the Use of Machine Learning to Predict Survival Outcomes After Transplant in Myelofibrosis

May 19th 2025

Adrián Mosquera Orgueira, MD, PhD, discusses research to improve machine learning models for predicting post-transplant survival outcomes in myelofibrosis.

Dr Kahl on the Rationale for Adding Bortezomib to BR Induction in MCL

May 19th 2025

Brad S. Kahl, MD, explains the importance of identifying less intensive induction regimens for older patients with mantle cell lymphoma.

Dr LeVee on ADC Trials That May Inform the Evolution of Breast Cancer Management

May 19th 2025

Alexis LeVee, MD, discusses clinical trials investigating ADCs that may change treatment standards for patients with various subtypes of breast cancer.

Dr Dreyling on Investigating ASCT Plus Ibrutinib and R-CHOP in Younger, Fit Patients With MCL

May 19th 2025

Martin Dreyling, MD, discusses the patient population studied in the TRIANGLE trial of ASCT plus ibrutinib-containing therapy in younger patients with MCL.

FDA Awards RMAT Designation to BCB-276 CAR T-Cell Therapy for Diffuse Intrinsic Pontine Glioma

May 19th 2025

The B7-H3–directed CAR T-cell therapy BCB-276 received RMAT designation for the treatment of patients with diffuse intrinsic pontine glioma.

FDA Grants Fast Track Designation to DLL3-Targeted ADC ZL-1310 in ES-SCLC

May 19th 2025

The DLL3-targeted antibody-drug conjugate ZL-1310 has received FDA fast track designation for patients with extensive-stage small cell lung cancer.

Belantamab Mafodotin–Based Combos Win Japanese Approval for R/R Myeloma

May 19th 2025

Two belantamab mafodotin–based combinations have been approved in Japan for relapsed/refractory multiple myeloma.

Hematology Experts Outline the Top Abstracts to Watch at the 2025 ASCO Annual Meeting

May 19th 2025

Oncology experts detail their most highly-anticipated hematology abstracts and data to watch at the upcoming 2025 ASCO Annual Meeting.

Dr Vlachou on the Rationale for Evaluating Perioperative Enfortumab Vedotin Plus Pembrolizumab in Upper Tract Urothelial CancerCancer

May 16th 2025

Evangelia Vlachou, MD, discusses the investigation of enfortumab vedotin plus pembrolizumab as perioperative therapy in upper tract urothelial cancer.

Dr Oluwole on the Importance of Assessing the Onset and Incidence of Axi-Cel–Related Neurotoxicity in R/R DLBCL

May 16th 2025

Olalekan O. Oluwole, MD, MPH, discusses how AE assessment could guide post-infusion monitoring periods and outpatient axi-cel administration in LBCL.

Dr Ali on the Efficacy of CDK4/6 Inhibition in ER+, HER2+ Breast Cancer

May 16th 2025

Azka Ali, MD, discusses how data from the PATINA trial inform the role of CDK4/6 inhibition in ER-positive, HER2-positive breast cancer.

Dr Tarantino on the Potential Relevance of the DESTINY-Breast09 Trial in HER2+ Breast Cancer

May 16th 2025

Paolo Tarantino, MD, PhD, discusses potentially practice-changing breast cancer research that will be presented at the 2025 ASCO Annual Meeting.